- Home
- DLR vs MRNA Comparison
DLR vs MRNA Comparison
Compare DLR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLR | MRNA |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.6B | 61.6B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DLR | MRNA |
|---|---|---|
| Price | $183.79 | $249.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 34 | 23 |
| Target Price | ★ $224.22 | $138.37 |
| AVG Volume (30 Days) | 2.1M | ★ 16.4M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 122.36 | 21.77 |
| EPS | ★ 0.46 | N/A |
| Revenue | $6,112,692,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $20.01 | $8.13 |
| Revenue Next Year | $11.13 | $16.26 |
| P/E Ratio | $390.30 | ★ N/A |
| Revenue Growth | ★ 10.04 | 4.29 |
| 52 Week Low | $146.23 | $22.28 |
| 52 Week High | $208.14 | $254.48 |
Technical Indicators
Market Signals| Indicator | DLR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 58.94 |
| Support Level | $179.08 | $181.02 |
| Resistance Level | $184.62 | $254.48 |
| Average True Range (ATR) | 5.06 | 22.65 |
| MACD | 0.85 | -2.16 |
| Stochastic Oscillator | 69.24 | 63.75 |
Price Performance
Historical ComparisonAbout DLR Digital Realty Trust Inc.
Digital Realty is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and large businesses. Digital Realty operates 300 properties in 57 metropolitan areas across 31 countries, serving 5,000 customers. Renting physical space accounts for about 90% of Digital Realty's revenue. The firm enables hyperscalers and other clients to store servers, data, and networking equipment. The other 10% of revenue is generated primarily through interconnection services (8%) and other fee income (2%).
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.